Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat

与Curevo、LimmaTech Biologics和Vaccine Company达成的协议针对与长期神经学和肿瘤学风险相关的病毒病原体，以及难以预防或治疗的细菌病原体。

Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious disease

收购建立在礼来传染病的传统之上，并加强了其对减少严重疾病长期负担的预防策略的承诺。

INDIANAPOLIS

印第安纳波利斯

,

，

May 26, 2026

2026年5月26日

/PRNewswire/ -- Eli Lilly and Company (NYSE:

/PRNewswire/ -- 礼来公司（纽约证券交易所代码：

LLY

礼来公司

) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transactions advance Lilly's strategy of investing in differentiated technology platforms to address significant health problems..

）今天宣布了收购三家公司的协议，这三家公司分别是Curevo Inc.（Curevo）、LimmaTech Biologics AG（LimmaTech Biologics）和Vaccine Company, Inc.（Vaccine Company），此举将扩大其在传染病领域的研发工作。这些交易推动了礼来公司投资于差异化技术平台以解决重大健康问题的战略。

For 150 years, Lilly has advanced medicines to address the world's most pressing health challenges. Infectious diseases remain a major source of global morbidity, both in their acute presentation and in the downstream health consequences of primary infection.

150年来，礼来公司一直在推进药物研发，以应对世界上最紧迫的健康挑战。传染病仍然是全球发病率的主要来源，无论是在其急性表现还是原发感染带来的下游健康后果方面。

'These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,' said Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president, Lilly Research Laboratories. 'Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility.

“这些收购反映了一种深思熟虑的战略，即在疾病源头进行预防，而不是治疗其后果，”医学博士、哲学博士、首席科学与产品官、礼来研究实验室总裁丹尼尔·M.斯科夫隆斯基表示。“数十年的证据现已将常见感染与多年后可能显现的疾病联系起来，包括神经系统疾病、癌症和不孕症。”

And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory.'.

随着抗菌素耐药性削弱我们治疗细菌感染的能力，疫苗正日益成为预防的唯一途径。将这些公司的平台和团队与礼来的全球规模相结合，使我们能够改变这一轨迹。

Curevo's

Curevo的

lead product candidate is amezosvatein, an adjuvanted subunit vaccine for the prevention of shingles in adults. While the current standard of care for shingles prevention is effective, tolerability challenges can limit the overall vaccination rates and contribute to second-dose hesitancy, leaving a meaningful portion of patients with reduced or no protection against shingles and its long-term consequences.

主要候选产品是amezosvatein，一种佐剂亚单位疫苗，用于预防成人带状疱疹。尽管目前带状疱疹预防的标准疗法有效，但耐受性问题可能会限制整体接种率，并导致第二剂接种犹豫，使相当一部分患者的带状疱疹及其长期后果的防护减弱或缺失。

Amezosvatein was engineered with a next-generation synthetic adjuvant to overcome this problem. In a Phase 2 clinical trial head-to-head against the standard of care, amezosvatein matched immune response across all primary endpoints and reduced side effects such as activity-limiting fatigue, chills, and pain at the injection site by more than half.

Amezosvatein 采用下一代合成佐剂设计，以解决这一问题。在一项与标准治疗方案直接对比的 2 期临床试验中，amezosvatein 在所有主要终点上均达到了相同的免疫反应，并将限制活动的疲劳、寒战和注射部位疼痛等副作用减少了超过一半。

Given growing evidence linking shingles to elevated risk of stroke, and that shingles vaccination is associated with reduced dementia risk, a meaningfully better-tolerated vaccine could expand the reach of shingles prevention and reduce these long-term risks at a population level..

鉴于越来越多的证据表明带状疱疹与中风风险升高有关，且带状疱疹疫苗接种可降低痴呆风险，一种耐受性显著更好的疫苗可能会扩大带状疱疹预防的覆盖范围，并在人群层面降低这些长期风险。

Under the terms of the agreement, Lilly will acquire Curevo and Curevo shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payment upon achievement of a specified milestone.

根据协议条款，礼来公司将收购Curevo公司，Curevo公司的股东们最高可获得15亿美元的现金，其中包括一笔首付款以及在达到特定里程碑后支付的后续款项。

LimmaTech Biologics

林马泰克生物制品

is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including

正在开发针对细菌病原体的疫苗，这些病原体因抗菌素耐药性不断上升而使治疗选择逐渐减少，包括

Staphylococcus aureus

金黄色葡萄球菌

,

，

Neisseria gonorrhoeae

淋病奈瑟菌

, and

，以及

Chlamydia trachomatis

沙眼衣原体

. The company's proprietary platform is designed to generate broad, durable immune responses against complex bacterial targets by targeting the toxins and superantigens that drive disease. LimmaTech's lead program, LTB-SA7, is in Phase 1 development as a vaccine against

公司的专有平台旨在通过针对推动疾病的毒素和超抗原来产生对复杂细菌目标的广泛、持久的免疫反应。LimmaTech 的主导项目 LTB-SA7 作为一种疫苗正处于第一阶段的开发中，用于对抗

S. aureus

金黄色葡萄球菌

, the leading cause of surgical-site infection.  The company's preclinical pipeline is pursuing additional bacterial pathogens, including those that drive infertility and other long-term consequences of infection that fall disproportionately on women. A vaccine-led prevention strategy could change the trajectory of diseases that are becoming increasingly difficult to treat..

，是手术部位感染的主要原因。公司的临床前研发管线正在针对其他细菌病原体，包括那些导致不孕和其他对女性影响尤为严重的长期感染后果。以疫苗为主导的预防策略可能会改变那些越来越难以治疗的疾病的进程。

Under the terms of the agreement, Lilly will acquire LimmaTech for up to $780 million in cash, inclusive of an upfront payment and additional potential payments based upon the achievement of certain clinical and regulatory milestones.

根据协议条款，礼来公司将斥资高达7.8亿美元现金收购LimmaTech，其中包括首付款以及基于某些临床和监管里程碑达成情况的潜在额外付款。

Vaccine Company

疫苗公司

is developing proprietary In Vivo Nanoparticle (IVN) technologies designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production. The company is advancing a broad preclinical pipeline spanning multiple viral pathogens; the lead program applies this technology to Epstein-Barr Virus (EBV) with a five-antigen Phase 1-ready candidate.

正在开发专有的体内纳米颗粒（IVN）技术，旨在实现已知能够引发与病毒样颗粒疫苗相关的持久免疫反应的抗原展示，同时避免传统病毒样颗粒生产的制造负担。该公司正在推进涵盖多种病毒病原体的广泛临床前管线；其主导项目将此技术应用于爱泼斯坦-巴尔病毒（EBV），已拥有一个包含五种抗原的处于第一阶段准备就绪的候选药物。

Given the growing evidence linking EBV to multiple sclerosis and several malignancies, a prophylactic vaccine could prevent not only acute infectious mononucleosis but also the long-term neurological and oncological consequences that may follow infection..

鉴于越来越多的证据表明EBV与多发性硬化症和多种恶性肿瘤有关，一种预防性疫苗不仅可以防止急性传染性单核细胞增多症，还可以预防感染后可能出现的长期神经和肿瘤后果。

Under the terms of the agreement, Lilly will acquire Vaccine Company and Vaccine Company shareholders could receive up to $1.55 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical and commercial milestones.

根据协议条款，礼来公司将收购疫苗公司，疫苗公司股东可获得高达15.5亿美元的现金，其中包括首付款以及在实现某些临床和商业里程碑后的后续付款。

These transactions are subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Lilly will determine the accounting treatment of these transactions following closing in accordance with Generally Accepted Accounting Principles (GAAP).

这些交易受惯例成交条件的约束，包括《1976年哈特-斯科特-罗迪诺反托拉斯改进法》规定的等待期届满。礼来公司将在交易完成后根据公认会计原则（GAAP）确定这些交易的会计处理方法。

These transactions will thereafter be reflected in Lilly's financial results and financial guidance..

这些交易随后将反映在礼来的财务业绩和财务指引中。

About Lilly

关于Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治疗手段，以改善世界各地人们的生活。150年来，我们一直在开创改变生命的发现，如今我们的药物帮助了全球数千万人。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转变为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. To learn more, visit .

每朝着更健康的世界迈出一步，我们都受到一个目标的激励：让更多数百万人的生活更美好。欲了解更多信息，请访问。

Lilly.com

莉莉网

and

和

Lilly.com/news

Lilly.com/新闻

, or follow us on

，或者关注我们

Facebook

Facebook

,

，

Instagram

图片分享社交平台

, and

，以及

LinkedIn

领英

. F-LLY

. F-LLY

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly's proposed acquisitions of Curevo, LimmaTech and Vaccine Company (collectively, the 'Companies'), the anticipated benefits of the proposed acquisitions, potential contingent consideration amounts and terms, the applicable parties' ability to satisfy the conditions to the consummation of the proposed acquisitions, each Company's product candidates and ongoing clinical and preclinical development, Lilly's infectious disease business and strategy, expansion of research and development efforts in infectious diseases and potential development of programs, product candidates and medicines to address infectious diseases, and the accounting treatment of the proposed acquisitions under GAAP and their potential impact on Lilly's financial results and financial guidance, and reflects Lilly's current beliefs and expectations.

本新闻稿包含关于礼来公司拟收购Curevo、LimmaTech和Vaccine Company（统称为“公司”）的前瞻性声明（该术语定义见1995年《私人证券诉讼改革法案》），涉及拟议收购的预期收益、潜在的或有对价金额与条款、相关方完成拟议收购的条件满足能力、各公司的候选产品及其正在进行的临床和临床前开发、礼来公司的传染病业务与战略、传染病领域研发工作的扩展、针对传染病的潜在项目、候选产品和药物开发，以及拟议收购在GAAP下的会计处理及其对礼来财务业绩和财务指引的潜在影响，并反映了礼来当前的信念与期望。

However, as with any such undertaking, there are substantial risks and uncertainties in closing and implementing the proposed acquisitions and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will close the proposed acquisitions or realize the expected benefits of the proposed acquisitions, that the proposed acquisitions will achieve the results discussed in this release, or that the proposed acquisitions will yield commercially successful products.

然而，与任何此类行动一样，在完成和实施拟议的收购以及药物研发、开发和商业化的过程中，存在重大的风险和不确定性。其中，不能保证礼来公司将完成拟议的收购或实现预期的收购效益，也不能保证拟议的收购将取得本公告中讨论的结果，或者拟议的收购将产生商业上成功的产品。

The Companies' product candidates are investigational and have not been approved by any regulatory authority. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with .

这些公司的产品候选物正在研究中，尚未获得任何监管机构的批准。有关这些以及其他可能导致实际结果与礼来公司预期不同的风险和不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的Form 10-K和Form 10-Q报告。

Refer to:

参考：

Ashley Hennessey;

艾希礼·亨尼西；

[email protected]

电子邮件地址

; 317-416-4363 (Media)

；317-416-4363（媒体）

Michael Czapar;

迈克尔·查帕尔；

[email protected]

电子邮件地址

; 317-617-0983 (Investors)

；317-617-0983（投资者）

SOURCE Eli Lilly and Company

来源：礼来公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示